Anti-Infective Agents Market Size, Share and Growth Analysis

Anti-Infective Agents Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Anti-Viral, Anti-Bacterial, Anti-Fungal, and Others), Range (Narrow Spectrum and Broad Spectrum),  Route of Administration (IV, Oral, Topical, and Others) Indication (HIV, Tuberculosis, Respiratory Infection, Pneumonia, and Others) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-Commerce, and Others)

Publication Month : Jul 2022

  • Report Code : TIPRE00004201
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 241
Inquire Before Buy

PRICING

$4550

$3640

The anti-infective agents market is expected to grow from US$ 1,35,961.03 million in 2022 to US$ 1,64,196.61 million by 2028; it is estimated to grow at a CAGR of 3.19% from 2022 to 2028.

Anti-infectives are medications that help in preventing and treating infections, such as anti-bacterial, anti-viral, anti-fungal, and antiparasitic medications. Anti-infective therapies help in the treatment of minor infections and many serious infectious diseases such as tuberculosis and pneumonia. These therapies have revolutionized healthcare as they enrich and extend the life of patients suffering from all types of infectious diseases.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Anti-Infective Agents Market: Strategic Insights

anti-infective-agents-market
Market Size Value inUS$ 1,35,961.03 Million in 2022
Market Size Value byUS$ 1,64,196.61 Million by 2028
Growth rateCAGR of 3.19% from 2022 to 2028
Forecast Period2022-2028
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

The anti-infective agents market is segmented into type, range, route of administration, indication, distribution channel, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends and market dynamics and the competitive analysis of the globally leading market players.       

Lucrative Regions for Anti-Infective Agents Market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Market Insights

Rising Government Support for Research Activities & Clinical Trials and Rising Prevalence of Targeted Diseases Drive Anti-Infective Agents Market

The clinical trials industry has seen exceptional growth in the last 10 years. The US Food and Drug Administration (FDA) revealed in August 2019 that it had awarded 12 new clinical trial research grants that are over US$ 15 million for the next 4 years to improve the development of medical products for patients with rare diseases. The grants were conferred to principal investigators from industry and academics across the US. The FDA awarded grants through the Orphan Products Clinical Trials Grants Program, which congress funds to promote the clinical development of medical foods, biologics, drugs, and medical devices to treat rare diseases. Grants are intended to considerably contribute to the marketing approval of products to treat rare diseases and provide essential data for developing such products. For clinical trials of possibly life-changing treatments for patients with rare diseases, the FDA has been offering much-needed financial support for over 35 years. In addition, the Orphan Products Clinical Trials Grants Program's contributions have supported research that will lead to the marketing approval of treatments for rare diseases in the coming years.

COVID-19 vaccines are developing significantly because more participants are focusing on clinical trials and collaborating to register rapid growth and sufficient production capacity. In addition, the UK government has committed to providing US$ 99.9 million (£84 million) in funding and manufacturing support to researchers to work on the COVID-19 vaccine program.

A few examples of developments that have promoted the growth of the anti-infective agents market are listed below:

  • In Oct 2022, Merck expanded its vaccine manufacturing facility in Elkton, VA.
  • In Jun 2022, Merck's VAXNEUVANCE drug for Prevention of Invasive Pneumococcal Disease in Infants and Children was approved by US FDA.
  • In May 2022, group sales increased by 11% (10% in CHF) to US$ 17.12 billion in the first quarter of the year. This will encourage the company to make better investments and expand.
  • In Feb 2022, Roche announced the expansion of the COVID-19 PCR portfolio to the cobas 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests.
  • In May 2022, the FDA lifted the clinical hold placed on the Gilead Sciences Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).
  • In Apr 2022, the FDA approved a supplemental new drug application of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients under 12 years with COVID-19.
  • In Apr 2022, Sandoz, a Novartis Division, announced the extension of its collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
  • In Apr 2022, Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.

Product Insights

Based on type, the anti-infective agents market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment is expected to hold the largest share of the market in 2022. However, the anti-fungal segment is anticipated to register the highest CAGR during the forecast period. An anti-fungal agent is a drug that selectively eliminates fungal pathogens from a host with low toxicity to the host. Anti-fungal medications are available in various forms, including antimetabolite anti-fungal medicines, allylamine and morpholine anti-fungal medicines, polyene anti-fungal medicines, and azole anti-fungal medicines. Systemic and superficial infections, such as skin, eyes, mouth, and vagina infections, can all be caused by fungi. Athlete's foot, ringworm, and fungal meningitis are a few of the disorders that are typically treated using anti-fungal agents with fungicidal activity. Further, increasing numbers of patients with infectious disorders and hospital-acquired or nosocomial infections are anticipated to fuel the market growth. According to the Centers for Diseases Control and Prevention, ~46,000 new cases of invasive candidiasis, a prevalent bloodstream infection in the US, arise each year. Moreover, as per an article published in the National Centre for Biotechnology (NCBI) in 2019, it is estimated that ~1 million cases of cryptococcosis were recorded annually, resulting in 625,000 deaths globally. Thus, the rise in cases of infectious diseases is driving the anti-infective agents market growth.

Anti-Infective Agents Market, by type – 2022 and 2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Range Insights

Based on range, the anti-infective agents market is bifurcated into narrow spectrum and broad spectrum. The narrow spectrum segment is expected to hold a larger market share in 2022. However, the broad spectrum segment is anticipated to register a higher CAGR during the forecast period. Narrow spectrum antibiotics are effective against only a limited range of organisms. Furthermore, the advancements in the treatment are likely to develop more advanced drugs in the coming years. When the causative agent is recognized, narrow spectrum antibiotics are utilized to treat the specific infection since they do not destroy as many normal microorganisms as broad spectrum antibiotics. Therefore, it is less likely to result in superinfection. This reduces bacterial resistance since they exclusively affect certain types of bacteria, such as Azithromycin (a macrolide antibiotic belonging to the azalide subclass) and Clarithromycin. Several global players have well-established R&D with an increased focus on the development of narrow spectrum drugs to avoid the occurrence of multidrug-resistant organisms.

Anti-Infective Agents – Market Segmentation

The anti-infective agents market is segmented into type, range, route of administration, indication, distribution channel, and geography. Based on type, the market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. Based on range, the anti-infective agents market is bifurcated into narrow spectrum and broad spectrum. Based on route of administration, the anti-infective agents market is segmented into IV, oral, topical, and others. Based on indication, the anti-infective agents market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. Based on distribution channel, the anti-infective agents market is categorized into hospital pharmacies, retail pharmacies, specialty pharmacies, e-commerce, and others. By geography, the anti-infective agents market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).  

Company Profiles

Abbott; Allergan Plc.; Astellas Pharma Inc.; Merck & Co., Inc.; Bayer AG; Bristol-Myers Squibb Company; Boehringer Ingelheim International GmbH; F. HOFFMANN-LA ROCHE Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; and Novartis AG are the leading companies operating in the global anti-infective agents market. 

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Range, Route of Administration, Indication, and Distribution Channel

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is the anti-infective agents market?

Anti-infectives are medications that help in preventing and treating infections, these include antibacterial, antivirals, antifungals and antiparasitic medications. Anti-infective therapies help in treating minor infections as well as many serious infectious diseases tuberculosis or pneumonia. These therapies have revolutionized healthcare as they enrich and extend life of patents suffering from all types of infectious diseases

What are the driving factors for the anti-infective agents market across the country?

Factors such as the rising prevalence of targeted diseases and rising government support for research activities and clinical trials.

What are the restraining factors for the anti-infective agents market across the country?

Emergence of anti-infective drugs resistance and side effects associated with anti-infective drugs is expected to restrict the market growth during the forecast period

Who are the major players in market the anti-infective agents market?

The anti-infective agents market majorly consists of the players such as Abbott Laboratories, Inc., Allergan Plc., Astellas Pharma Inc., Merck and Co., Inc., Bayer AG, Bristol-Myers Squibb Co., Boehringer Ingelheim, F. Hoffman-La Roche Ltd., Gilead Sciences, Glaxosmithkline Plc, and Novartis AG.

Which segment is dominating the anti-infective agents market?

The global anti-infective agents market based on type, is segmented into anti-viral, anti-bacterial, anti-fungal, and anti-parasitic drug. In 2022, anti-viral segment held largest market share and the segment is estimated to grow at the fastest CAGR during the forecast period.

Which region is dominating the anti-infective agents market?

The global anti-infective agents market on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and the South & Central America. In 2022, North American region held largest market share. However, Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period

The List of Companies - Anti-Infective Agents Market

  1. Abbott
  2. Allergan Plc.
  3. Astellas Pharma Inc.
  4. Merck & Co., Inc.
  5. Bayer AG
  6. Bristol-Myers Squibb Company
  7. Boehringer Ingelheim International GmbH
  8. F. Hoffmann-La Roche Ltd.
  9. Gilead Sciences, Inc.
  10. GlaxoSmithKline plc.
  11. Novartis AG

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Anti-Infective Agents Market